Pcl Nanoparticles For Retinal Drug Delivery Of A Small Molecule Inhibitor Of Runx1

Purpose: Most of the current treatments for diseases affecting the retina include topical administration, drug eluting intravitreal implants, or intravitreal injections. However, developing effective ocular drug delivery systems is one of the major challenges in ophthalmology due to anatomical and physiological barriers in the eye. This study aimed to develop Polycaprolactone (PCL) nanoparticles as an injectable slow release-drug delivery system for the posterior segment of the eye. We formulated a small molecule inhibitor of RUNX1 as it has been shown to play a critical role in aberrant angiogenesis.Methods: Briefly, Ro5-3335 (RUNX1 inhibitor) was added to the prepolymer solution. The mixture was transferred to ice and sonicated (200W). This was added into a 1% w/v polyvinyl alcohol (PVA) solution and sonicated (500W). The primary emulsion was poured into a 0.5% w/v PVA solution. The organic phase was …